G R Y De Meyer
Overview
Explore the profile of G R Y De Meyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Dominicis C, Perrotta P, DallAngelo S, Wyffels L, Staelens S, De Meyer G, et al.
ACS Med Chem Lett
. 2020 May;
11(5):933-939.
PMID: 32435408
PFKFB3, a glycolysis-related enzyme upregulated in inflammatory conditions and angiogenesis, is an emerging target for diagnosis and therapy of atherosclerosis. The fluorinated phenoxindazole [F] was synthesized, radiolabeled in 17 ±...
2.
[Frequency and nature of drug related problems with corticosteroids in Belgian community pharmacies]
Lelubre M, Koubaity M, De WuLf I, Boussery K, De Meyer G, Foulon V, et al.
J Pharm Belg
. 2018 Oct;
(3):32-41.
PMID: 30281242
Aim Aims are: 1] Identify causes of Drug Related Problems (DRPs), interventions performed by pharmacists and results of corticosteroid- related problems and 2] distinguish between problems related to inhaled and...
3.
Roth L, Schrijvers D, Martinet W, De Meyer G
Acta Cardiol
. 2016 Sep;
71(4):483-8.
PMID: 27594365
No abstract available.
4.
Van der Donckt C, Roth L, Vanhoutte G, Blockx I, Bink D, Ritz K, et al.
Neuroscience
. 2015 Mar;
295:11-22.
PMID: 25797463
We recently reported that apolipoprotein E (ApoE)-deficient mice with a mutation in the fibrillin-1 gene (ApoE(-/-)Fbn1(C1039G+/-)) develop accelerated atherosclerosis with enhanced inflammation, atherosclerotic plaque rupture, myocardial infarction and sudden death....
5.
Huysmans K, De WuLf I, Foulon V, De Loof H, Steurbaut S, Boussery K, et al.
J Pharm Belg
. 2014 May;
(1):4-15.
PMID: 24804389
Introduction: The identification, the management and if possible the prevention of drug related problems (DRP), are the main responsibilities of pharmacists. Aim: The aims of the study were 1/to investigate...
6.
Fraeyman J, De Winter J, De Loof H, van Hal G, Beutels P, Remmen R, et al.
J Pharm Belg
. 2013 Jun;
(2):18-31.
PMID: 23798183
Introduction: Since 2002 in Belgium, physicians are allowed to prescribe by International Non-proprietary Name (INN). In 2005, the conditions for this decree were set. Examples from other countries have shown...
7.
Schillemans S, De Loof H, De Meyer G
J Pharm Belg
. 2013 Jan;
(4):4-13.
PMID: 23350206
Due to the increasing complexity of medication regimens it is not always easy for the pharmacist to quickly and effectively screen the drug use of a particular patient for interactions....
8.
Fraeyman J, van Hal G, De Loof H, Remmen R, De Meyer G, Beutels P
Acta Clin Belg
. 2012 Aug;
67(3):160-71.
PMID: 22897063
Background: Pharmaceutical expenditures are increasing as a proportion of health expenditures in most rich countries. Antidepressants, acid blocking agents and cholesterol lowering medication are major contributors to medicine sales around...
9.
Janssen S, De Loof H, De Meyer G
J Pharm Belg
. 2011 Feb;
(4):118-29.
PMID: 21294318
No abstract available.
10.
Martinet W, Croons V, Timmermans J, Herman A, De Meyer G
Br J Pharmacol
. 2007 Aug;
152(4):493-500.
PMID: 17700714
Background And Purpose: Macrophages in atherosclerotic plaques have a tremendous impact on atherogenesis and plaque destabilization. We previously demonstrated that treatment of plaques in cholesterol-fed rabbits with the nitric oxide...